CG Oncology Inc. (CGON) Stock Grade

About CG Oncology Inc.'s fundamentals

CG Oncology is a biotechnology company with a market capitalization of $3.2 billion that has demonstrated exceptional revenue growth of 254.7% year-over-year, indicating rapidly expanding commercial activity. However, the company operates at a significant loss, with a net margin of -3985.0%, reflecting substantial expenses that far exceed current revenues—a common profile for early-stage biotech firms investing heavily in research, development, and commercialization. The company does not currently pay a dividend, and profitability metrics like P/E ratio and return on equity are not meaningful given the net loss position.